These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 7508268

  • 21. New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability.
    Arpicco S, Dosio F, Brusa P, Crosasso P, Cattel L.
    Bioconjug Chem; 1997; 8(3):327-37. PubMed ID: 9177838
    [Abstract] [Full Text] [Related]

  • 22. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
    Svensson HP, Vrudhula VM, Emswiler JE, MacMaster JF, Cosand WL, Senter PD, Wallace PM.
    Cancer Res; 1995 Jun 01; 55(11):2357-65. PubMed ID: 7757987
    [Abstract] [Full Text] [Related]

  • 23. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity.
    Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, Knipe JO, Lasch SJ, Trail PA.
    Bioconjug Chem; 2002 Jun 01; 13(4):855-69. PubMed ID: 12121142
    [Abstract] [Full Text] [Related]

  • 24. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains.
    King HD, Dubowchik GM, Mastalerz H, Willner D, Hofstead SJ, Firestone RA, Lasch SJ, Trail PA.
    J Med Chem; 2002 Sep 12; 45(19):4336-43. PubMed ID: 12213074
    [Abstract] [Full Text] [Related]

  • 25. Dipeptide-based highly potent doxorubicin antibody conjugates.
    Jeffrey SC, Nguyen MT, Andreyka JB, Meyer DL, Doronina SO, Senter PD.
    Bioorg Med Chem Lett; 2006 Jan 15; 16(2):358-62. PubMed ID: 16275070
    [Abstract] [Full Text] [Related]

  • 26. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers.
    Mueller BM, Wrasidlo WA, Reisfeld RA.
    Bioconjug Chem; 1990 Jan 15; 1(5):325-30. PubMed ID: 1711377
    [Abstract] [Full Text] [Related]

  • 27. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
    Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE.
    Science; 1993 Jul 09; 261(5118):212-5. PubMed ID: 8327892
    [Abstract] [Full Text] [Related]

  • 28. A carbohydrate-directed heterobifunctional cross-linking reagent for the synthesis of immunoconjugates.
    Zara JJ, Wood RD, Boon P, Kim CH, Pomato N, Bredehorst R, Vogel CW.
    Anal Biochem; 1991 Apr 09; 194(1):156-62. PubMed ID: 1867379
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Determination of immunoreactivity of doxorubicin antibody immunoconjugates by a Le(y) competitive RIA.
    Zhao H, Willner D, Cleaveland JS, Braslawsky GR, Brown JP.
    Bioconjug Chem; 1992 Apr 09; 3(6):549-53. PubMed ID: 1361153
    [Abstract] [Full Text] [Related]

  • 32. Enhanced stability in vitro and in vivo of immunoconjugates prepared with 5-methyl-2-iminothiolane.
    Carroll SF, Bernhard SL, Goff DA, Bauer RJ, Leach W, Kung AH.
    Bioconjug Chem; 1994 Apr 09; 5(3):248-56. PubMed ID: 7918744
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
    Kratz F, Ehling G, Kauffmann HM, Unger C.
    Hum Exp Toxicol; 2007 Jan 09; 26(1):19-35. PubMed ID: 17334177
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
    Sjögren HO, Isaksson M, Willner D, Hellström I, Hellström KE, Trail PA.
    Cancer Res; 1997 Oct 15; 57(20):4530-6. PubMed ID: 9377565
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.